JHOP - February 2020 Vol 10, No 1

Robert Mancini, PharmD, BCOP; Mallori Hooker, NP-C, AOCNP, BMTCN; William Kreisle, MD

Hypersensitivity Rates in Pediatric Patients Receiving Intravenous or Intramuscular Asparaginase Agents

Zachery Halford, PharmD, BCOP, BCPPS; Megan Park, PharmD, MBA, DPLA

Subcutaneous versus Intravenous Granulocyte Colony-Stimulating Factor to Enhance Neutrophil Engraftment in Patients Undergoing Hematopoietic Stem-Cell Transplant

Samantha L. Ellingson, PharmD, BCPS; Diwura Owolabi, PharmD, BCOP; Susan Wheelis, PharmD, BCOP; Carrie S. Oliphant, PharmD, FCCP, BCPS, BCCP; Yasser Khaled, MD

Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing

Joshua A. Roth, PhD, MHA; Theo deVos, PhD; Scott D. Ramsey, MD, PhD

Symptom Management Overview

Clostridium difficile Infection Management in Adults Undergoing Stem-Cell Transplant

Tetyana Melnyk, PharmD

FDA Oncology Update

Recent Cancer Drugs Approved by the FDA

ASH Highlights

Meeting Highlights

Mosunetuzumab, a Dual-Targeted Antibody, Shows Complete Remissions in Relapsed/Refractory NHL After CAR T-Cell Therapy

Meeting Highlights

Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy Prevents Cytokine Release Syndrome

Meeting Highlights

Zanubrutinib, Next-Generation BTK, Leads to Impressive Responses in Patients with CLL or SLL

Meeting Highlights

First-Line Acalabrutinib-Based Triplet Therapy Leads to Undetectable Minimal Residual Disease in CLL

Meeting Highlights

Investigational Oral Form of Azacitidine Improves Survival Maintenance Therapy in Patients with Acute Myeloid Leukemia

Meeting Highlights

All-Oral Time-Limited Combination Treatment for CLL or SLL Shows Early Impressive Efficacy

Meeting Highlights

Tazemetostat, First-in-Class EZH2 Inhibitor, Shows Impressive Activity in Relapsed or Refractory Follicular Lymphoma

Meeting Highlights

Nivolumab Monotherapy as Bridge to Transplant in Patients with Relapsed or Refractory Hodgkin Lymphoma

Meeting Highlights

Investigational BET Inhibitor, CPI-0610, Promotes Responses in Myelofibrosis

Meeting Highlights

Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma

Meeting Highlights

Dual-Targeted CAR T-Cell Therapy Leads to Very High Response Rates in Relapsed or Refractory Multiple Myeloma

JHOP - February 2020 Vol 10, No 1

Subscribe Today!

I'd like to receive: